Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer

BACKGROUND: The V325 study showed that docetaxel, cisplatin, and fluorouracil (DCF) prolonged overall survival (OS) of patients with advanced gastric cancer, but with a high incidence of dose-limiting toxicities. We investigated the efficacy and safety of a modified DCF (mDCF) regimen for Chinese pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jinwan, Xu, Ruihua, Li, Jian, Bai, Yuxian, Liu, Tianshu, Jiao, Shunchang, Dai, Guanghai, Xu, Jianming, Liu, Yunpeng, Fan, Nanfeng, Shu, Yongqian, Ba, Yi, Ma, Dong, Qin, Shukui, Zheng, Leizhen, Chen, Weichang, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688303/
https://www.ncbi.nlm.nih.gov/pubmed/25604851
http://dx.doi.org/10.1007/s10120-015-0457-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688303/
https://www.ncbi.nlm.nih.gov/pubmed/25604851
http://dx.doi.org/10.1007/s10120-015-0457-4

Ejemplares similares